<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Placenta accreta spectrum: Management
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Placenta accreta spectrum: Management
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Placenta accreta spectrum: Management
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Robert M Silver, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Charles J Lockwood, MD, MHCM
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Lynn L Simpson, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Vanessa A Barss, MD, FACOG
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Oct 18, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1320673">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Management of patients with placenta accreta spectrum (PAS; placenta accreta, increta, or percreta) varies widely in the United States [
         <a href="#rid1">
          1,2
         </a>
         ]. Although the impact of PAS on pregnancy outcomes is well described, no randomized trials and few studies have examined the management of pregnancies complicated by this disorder. As a result, recommendations for its management are based on case series and reports, personal experience, expert opinion, and good clinical judgment.
        </p>
        <p>
         The management of PAS will be discussed here and is essentially the same, except when a percreta extends to extrauterine tissue. Unless otherwise noted, the following discussion of management of PAS applies to all depths of placental invasion. The clinical features, diagnosis, and potential consequences of PAS are reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/6759.html" rel="external">
          "Placenta accreta spectrum: Clinical features, diagnosis, and potential consequences"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1320680">
         <span class="h1">
          PRENATAL CARE
         </span>
         <span class="headingEndMark">
          —
         </span>
         All patients with suspected PAS based on clinical risk factors and suggestive ultrasound findings should be counseled about the diagnosis and potential sequelae (eg, hemorrhage, blood transfusion, cesarean hysterectomy, maternal intensive care unit admission). Consultation with a maternal-fetal medicine specialist is desirable, and transfer to a center of excellence for placenta accreta is strongly advised [
         <a href="#rid1">
          1
         </a>
         ]. At a minimum, in the United States, patients should deliver at a facility where they can receive level III maternal care [
         <a href="#rid2">
          2
         </a>
         ]. Some women may consider pregnancy termination, but no data are available regarding whether and how much this may reduce maternal risk once the second trimester is reached. Removal of a cesarean scar pregnancy in the first trimester is highly likely to reduce maternal risk. (See
         <a class="medical medical_review" href="/z/d/html/131912.html" rel="external">
          "Cesarean scar pregnancy"
         </a>
         .)
        </p>
        <p>
         For patients with placenta previa-accreta, prenatal care follows typical guidelines for management of placenta previa; however, the combination of PAS and placenta previa is associated with an increased risk of severe maternal and surgical morbidities compared with PAS alone [
         <a href="#rid3">
          3
         </a>
         ] (see
         <a class="medical medical_review" href="/z/d/html/6809.html" rel="external">
          "Placenta previa: Management"
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Correction of iron deficiency anemia, if present. (See
         <a class="medical medical_review" href="/z/d/html/115637.html" rel="external">
          "Anemia in pregnancy", section on 'Treatment of iron deficiency'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Antenatal
         <a class="drug drug_general" data-topicid="9139" href="/z/d/drug information/9139.html" rel="external">
          betamethasone
         </a>
         between 23 and 34 weeks of gestation for pregnancies at increased risk of delivery within seven days (eg, antepartum bleeding).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9858" href="/z/d/drug information/9858.html" rel="external">
          Anti-D immune globulin
         </a>
         if vaginal bleeding occurs and the patient is RhD-negative.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Avoidance of pelvic examination and rigorous physical activity. Many clinicians recommend avoidance of sexual activity, although any benefit is unproven.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Consideration of hospitalization in the third trimester in the setting of vaginal bleeding, contractions, or residence at a remote distance from a center of excellence for PAS. Asymptomatic women can be followed as outpatients if they are appropriately counseled and can get to the hospital rapidly if symptoms develop [
         <a href="#rid4">
          4
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Autologous blood donation is generally not useful because most patients who require transfusion at delivery require more units than they can safely donate prenatally.
        </p>
        <p>
         Nonstress tests and/or biophysical profile scores are not performed routinely but are used in pregnancies that have standard indications for these tests (eg, fetal growth restriction, preeclampsia). (See
         <a class="medical medical_review" href="/z/d/html/457.html" rel="external">
          "Overview of antepartum fetal assessment"
         </a>
         .)
        </p>
        <p>
         Serial sonographic assessment of the placenta is generally not useful after the diagnosis of PAS has been made. However, a sonogram at 32 to 34 weeks can precisely locate the placenta and help to assess the likelihood of bladder involvement. This information is useful for surgical planning and delivery [
         <a href="#rid5">
          5
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1320687">
         <span class="h1">
          PREPARATION FOR DELIVERY
         </span>
        </p>
        <p class="headingAnchor" id="H1320695">
         <span class="h2">
          Components of preoperative planning
         </span>
         <span class="headingEndMark">
          —
         </span>
         It is critical to develop a plan preoperatively for managing women with a high likelihood of PAS. The goal is to provide information (informed consent) and plan interventions that will reduce the risk of massive postpartum hemorrhage, as well as its substantial morbidity and potential mortality. Cesarean hysterectomy is usually performed because the placenta cannot be removed in any other way and, if left in situ, subinvolution often results in postpartum hemorrhage.
        </p>
        <p>
         Specific components of preoperative planning and care that should be addressed include [
         <a href="#rid6">
          6
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Informed consent
         </strong>
         – Discussion of potential intraoperative complications and interventions (eg, severe hemorrhage, blood transfusion, injury to or partial resection of bladder and bowel, hysterectomy to control bleeding, risk of postoperative vesicovaginal fistula). (See
         <a class="medical medical_review" href="/z/d/html/6759.html" rel="external">
          "Placenta accreta spectrum: Clinical features, diagnosis, and potential consequences", section on 'Consequences'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Multidisciplinary care team
         </strong>
         – Management by a multidisciplinary team and delivery in a tertiary care facility improve outcomes and lower complication rates [
         <a href="#rid7">
          7-10
         </a>
         ]. We schedule a multidisciplinary conference with all key care participants at least two weeks prior to planned delivery to ensure that all necessary preparations are completed, and management plans implemented.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The multidisciplinary team includes maternal-fetal medicine specialists, anesthesiologists, neonatologists, interventional radiologists, pathologists, and blood bank and nursing personnel. It is desirable to have a surgeon in the operating room who has extensive experience with wide dissection of the parametrium and exploration of the retroperitoneum in the event this expertise is required for control of bleeding, bladder resection, and/or isolation, partial resection, and/or reimplantation of the ureters. Some obstetrician-gynecologists have this experience; general surgeons, urologists, and vascular surgeons also have expertise in this area. A urogynecologist, urologist, or gynecologic oncologist should be consulted in cases in which there is expected bladder involvement or if the surgeon does not have the requisite surgical expertise.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         If an appropriate multidisciplinary team and support services are not available at the site the patient plans delivery, the patient should be transferred to a tertiary facility that has the capability to most effectively manage major intraoperative hemorrhage and provide postoperative intensive care.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Scheduled delivery
         </strong>
         – Delivery should be scheduled at a time with optimal availability of necessary personnel and facilities. Planned delivery is generally associated with less intraoperative blood loss than emergency delivery [
         <a href="#rid11">
          11-14
         </a>
         ], although emergency delivery at a center of excellence can result in outcomes similar to those with planned delivery [
         <a href="#rid10">
          10
         </a>
         ]. However, a substantial percentage of patients develops complications leading to delivery earlier than planned, especially those with placenta percreta [
         <a href="#rid15">
          15,16
         </a>
         ]. (See
         <a class="local">
          'Timing'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Delivery in an operating room with capability for fluoroscopy avoids the need to transfer patients to the radiology department when procedures by interventional radiologists are indicated [
         <a href="#rid17">
          17
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cesarean hysterectomy
         </strong>
         – In most cases, a definitive decision regarding conservative management or cesarean hysterectomy should be made preoperatively. We, and others [
         <a href="#rid2">
          2,11,18,19
         </a>
         ], recommend cesarean hysterectomy, leaving the placenta undisturbed in situ when the prenatal diagnosis of PAS is reasonably certain based on imaging studies and/or clinical risk factors (placental implantation at the site of prior uterine surgery). This approach decreases blood loss and associated complications [
         <a href="#rid11">
          11,12
         </a>
         ]. However, conservative management is increasingly used to manage PAS. (See
         <a class="local">
          'Conservative management of placenta accreta'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Intravenous access
         </strong>
         – At least two large bore (14 gauge) intravenous catheters should be placed peripherally. For many patients, a central line offers no additional benefit and thus is not placed routinely. A rapid infuser is useful for administering warmed blood products and fluids at rapid rates.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Monitoring
         </strong>
         – Invasive arterial monitoring is commonly performed [
         <a href="#rid20">
          20
         </a>
         ]. Additional monitoring may include cardiac output monitors and transthoracic or
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww-sciencedirect-com.ezp-prod1.hul.harvard.edu%2Ftopics%2Fmedicine-and-dentistry%2Ftransesophageal-echocardiography&amp;token=AuqRRbXS4eruI%2BpxGwYUdopt9um9inEoyzbmAUGD3GXwyhUZ4eM23%2BLjEQSPcMbH1wzb8TbRxLXdlVZdZ1l08GDJQMYWA9TTufJ36KtB%2BkqSLISxPzS%2F5POQOC3VVKyfxwJiSCWZ6dMG9japAqxMcQ%3D%3D&amp;TOPIC_ID=83129" target="_blank">
          transesophageal echocardiography
         </a>
         (TEE). TEE is helpful in guiding changes in pharmacologic or fluid management, particularly in patients with life-threatening hemodynamic instability that persists despite corrective therapy. (See
         <a class="medical medical_review" href="/z/d/html/14943.html" rel="external">
          "Intraoperative transesophageal echocardiography for noncardiac surgery"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Thromboembolism prophylaxis
         </strong>
         – Pneumatic compression devices should be placed, given that surgery, major hemorrhage, and blood transfusion all increase the risk of postpartum venous thrombosis.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Blood products
         </strong>
         – We ensure availability of comprehensive blood product replacement. The blood bank should be notified, and adequate red blood cells, fresh frozen plasma, cryoprecipitate, and platelets should be available at delivery; the median estimated blood loss has been reported to be 2.5 to 7.8 liters [
         <a href="#rid8">
          8,11,13,21
         </a>
         ]. The magnitude of blood loss is difficult to predict antepartum [
         <a href="#rid22">
          22
         </a>
         ]. In a meta-analysis of 20 studies evaluating red blood cell use during delivery in nearly 1100 patients with PAS, the weighted mean number of units transfused was 5.19 (95% CI 4.12-6.26) per patient; however, methodologic inconsistencies among the studies and small cohort sizes limit the clinical utility of these findings [
         <a href="#rid23">
          23
         </a>
         ]. In the largest study (338 patients), the median number of units transfused was two but the range was 0 to 108 units, underscoring the variability in blood loss and the potential for horrific hemorrhage.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         A massive hemorrhage protocol is useful for managing laboratory evaluation and transfusion. An example of one hospital's protocol is shown in the algorithm  (
         <a class="graphic graphic_algorithm graphicRef91236" href="/z/d/graphic/91236.html" rel="external">
          algorithm 1
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/6710.html" rel="external">
          "Overview of postpartum hemorrhage"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7931.html" rel="external">
          "Massive blood transfusion"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Cell salvage
         </strong>
         – Use of intraoperative cell salvage may be considered. (See
         <a class="medical medical_review" href="/z/d/html/6712.html" rel="external">
          "Postpartum hemorrhage: Management approaches requiring laparotomy", section on 'Role of intraoperative cell salvage'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Patients who refuse blood transfusion
         </strong>
         – Counseling and options for patients who refuse blood transfusion are discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/7927.html" rel="external">
          "Approach to the patient who declines blood transfusion"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Drugs
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="10011" href="/z/d/drug information/10011.html" rel="external">
          Tranexamic acid
         </a>
         inhibits fibrin degradation and reduces the risk of death due to postpartum bleeding. However, efficacy specifically in PAS (either as treatment for active bleeding or as a prophylactic agent) is uncertain. (See
         <a class="medical medical_review" href="/z/d/html/6714.html" rel="external">
          "Postpartum hemorrhage: Medical and minimally invasive management", section on 'Administer tranexamic acid'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Use of recombinant VIIa for control of obstetric hemorrhage is under investigation; use specifically for bleeding from placenta accreta has not been widely reported. (See
         <a class="medical medical_review" href="/z/d/html/6714.html" rel="external">
          "Postpartum hemorrhage: Medical and minimally invasive management", section on 'Recombinant factor VIIa'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Bladder catheter and ureteral stents
         </strong>
         – A three-way Foley catheter and ureteral stents should be available in case they are needed to assess integrity of the urinary tract. This is critical in cases in which bladder resection is required.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Preoperative placement of ureteral stents may be useful in all women with PAS, especially those with a percreta, given the likelihood that hysterectomy will be complicated and adverse urologic events are more frequent and severe in this setting [
         <a href="#rid4">
          4,24
         </a>
         ]. Urologic morbidity occurred in approximately 20 percent of patients with PAS undergoing hysterectomy, 9 percent of patients with placenta accreta/increta, and 39 percent of patients with placenta percreta in a systematic review [
         <a href="#rid25">
          25
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Prophylactic stent placement was associated with a &gt;60 percent reduction in genitourinary injury (28 versus 51 percent; OR 0.37, 95% CI 0.21-0.65) in a retrospective series of 236 patients with PAS who underwent peripartum hysterectomy [
         <a href="#rid26">
          26
         </a>
         ]. However, in a meta-analysis including these and seven other studies of cesarean hysterectomy in 848 cases of prenatally suspected PAS, placement of prophylactic ureteral stents was not associated with a significant reduction in genitourinary injury, which occurred in approximately 26 percent of patients in both groups [
         <a href="#rid27">
          27
         </a>
         ]. A limitation of the analysis is that some studies did not require postnatal pathologic confirmation of PAS for inclusion in the study, thus potentially diluting the effect of the stents.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Although the utility of ureteral stents in PAS has not been established, many groups use them routinely in this setting as it is difficult to predict when they will be helpful, morbidity is low, and serious complications are rare [
         <a href="#rid28">
          28
         </a>
         ]. We use ureteral stents routinely when feasible.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Routine preoperative cystoscopy is not recommended (unless it is used to guide stent placement) [
         <a href="#rid4">
          4
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Anesthesia
         </strong>
         – General anesthesia is most commonly performed [
         <a href="#rid29">
          29
         </a>
         ]. Use of regional anesthesia (ie, continuous epidural) is increasing as it has been used successfully in scheduled deliveries and is preferred by some women [
         <a href="#rid29">
          29
         </a>
         ]. However, the team should be prepared to convert to general anesthesia if necessary [
         <a href="#rid30">
          30
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Positioning
         </strong>
         – Placing the patient in a lithotomy position or with legs flat on the table but separated provides access to the vagina and cervix, which can facilitate hysterectomy [
         <a href="#rid4">
          4
         </a>
         ]. It is also important to be able to assess bleeding through the vagina that may occur intraoperatively. Such bleeding may not be appreciated in the abdominal cavity until the patient has cardiovascular decompensation.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Postoperative care
         </strong>
         – An intensive care unit bed should be available for postoperative care, if needed. (See
         <a class="local">
          'Postoperative care'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1320709">
         <span class="h2">
          Endovascular intervention for hemorrhage control
         </span>
         <span class="headingEndMark">
          —
         </span>
         Prophylactic endovascular intervention with a balloon catheter in both internal iliac arteries, uterine artery embolization, or a combination of the two may be used to reduce bleeding during or after delivery. The choice depends on the operator's expertise and the available equipment. The value of endovascular intervention remains controversial, and it is not possible to predict which patients are most likely to benefit from this procedure [
         <a href="#rid4">
          4
         </a>
         ]. Until a large multicenter randomized trial is performed, the value of the procedure will not be clear.
        </p>
        <p>
         In a meta-analysis of endovascular interventional radiology procedures before surgery in over 950 pregnancies with PAS, the intervention was associated with reduced blood loss (mean difference -1.02 L, 95% CI -1.60 to -0.43 L) and a reduced risk of blood loss ≥2.5 L (odds ratio [OR] 0.18, 95% CI 0.04-0.78); however, this did not translate into a statistically significant reduction in red cell transfusion, and approximately 5 percent of patients had procedure-related complications [
         <a href="#rid31">
          31
         </a>
         ]. A meaningful comparison among techniques was not possible because of the small number of cases for some techniques and because the evidence was considered very low quality. Some observational studies have reported very favorable outcomes. In one such study comparing 28 patients who underwent balloon occlusion of the aorta or internal iliac arteries with 125 patients who did not undergo endovascular intervention, balloon occlusion was associated with a 31 percent decrease in blood loss and a 77 percent decrease in blood transfusions, and no patient required intensive care unit admission [
         <a href="#rid32">
          32
         </a>
         ]. In a simulation study, the collateral circulation and reversed flow in the uterine venules were major determinants of internal iliac artery balloon occlusion effectiveness [
         <a href="#rid33">
          33
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Risks
         </strong>
         – While catheter-related complications have been reported in small observational series (5 percent in the above meta-analysis [
         <a href="#rid31">
          31
         </a>
         ]), reliable data on complication rates in this clinical setting are not available. The risk of a vascular complication with percutaneous coronary artery intervention using femoral artery access, a well-established analogous procedure, is approximately 3 percent [
         <a href="#rid34">
          34-37
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Groin or retroperitoneal hematoma is the most common complication; most patients do not require transfusion. Rare cases of thrombotic and embolic complications requiring stent placement and/or arterial bypass have been reported in pregnant patients using endovascular hemorrhage control at delivery [
         <a href="#rid35">
          35
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Planning
         </strong>
         – If prophylactic endovascular intervention is planned, the patient should undergo delivery on a fluoroscopy table so that the procedure can be performed intraoperatively immediately after delivery of the infant.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Procedure
         </strong>
         – Preoperatively under fluoroscopic guidance, an angiographer inserts a catheter into each femoral artery and guides it to the desired target vessel. For embolization, an agent that allows for temporary vessel occlusion (eg, Gelfoam) is deployed after delivery of the infant.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For balloon occlusion, balloon-tipped catheters are introduced into the target artery. After delivery of the newborn, the balloons can be inflated intermittently for up to 20 minutes to reduce bleeding in the operative field, which facilitates placement of clamps and sutures and decreases total blood loss. Use of a pressure manometer-endoflator allows inflation and deflation of the balloons to pressure without the use of fluoroscopy [
         <a href="#rid38">
          38
         </a>
         ]. The catheters may be left in situ for several hours postoperatively and used for selective embolization of small pelvic vessels if postoperative bleeding occurs. They are removed under fluoroscopic guidance. In a modification of this standard approach, the balloon-tipped catheters are placed before surgery, the uterine and abdominal incisions are closed after the infant is delivered, and the patient is transferred to the angiography unit for embolization of the uteroplacental bed [
         <a href="#rid39">
          39
         </a>
         ]. The patient is then immediately returned to the operating room for hysterectomy. In eight cases in which this staged procedure was utilized, blood loss was significantly less than that in patients undergoing hysterectomy without embolization (mean 553 versus 4517 mL). This approach requires further study to determine safety and efficacy compared with the standard approach.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Prophylactic use of resuscitative endovascular balloon occlusion of the aorta (REBOA) has been described in a small number of women with abnormal placentation. Because data of safety and efficacy in pregnant and postpartum patients are limited [
         <a href="#rid40">
          40-47
         </a>
         ] and the potential for morbidity is high (eg, thrombosis), we are not using it routinely but we believe that it may prove to have value, especially in patients at high risk for morbidity. Use of REBOA in nonobstetric settings is reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/16863.html" rel="external">
          "Endovascular methods for aortic control in trauma", section on 'REBOA technique'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1320723">
         <span class="h1">
          DELIVERY
         </span>
        </p>
        <p class="headingAnchor" id="H2246993111">
         <span class="h2">
          Timing
         </span>
         <span class="headingEndMark">
          —
         </span>
         A substantial percentage of patients develops complications, such as preterm prelabor rupture of membranes, preterm labor, or antepartum bleeding, leading to delivery earlier than planned. Women with active bleeding should be delivered without a delay to administer antenatal
         <a class="drug drug_general" data-topicid="9139" href="/z/d/drug information/9139.html" rel="external">
          betamethasone
         </a>
         [
         <a href="#rid48">
          48
         </a>
         ].
        </p>
        <p>
         The optimum gestational age for scheduled delivery is controversial, and high-quality data are lacking. The risks of preterm birth must be weighed against the risk of complications, such as bleeding, leading to emergency delivery under suboptimal circumstances.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For stable (no bleeding or preterm labor) patients, we advise planned delivery between 34+0 and 35+6 weeks of gestation, in agreement with the American College of Obstetricians and Gynecologists [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For women at high risk of emergency delivery before 34 weeks, planned delivery before 34 weeks may be reasonable, although outcomes are still favorable with emergency delivery in centers of excellence [
         <a href="#rid16">
          16,21
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Antenatal
         <a class="drug drug_general" data-topicid="9139" href="/z/d/drug information/9139.html" rel="external">
          betamethasone
         </a>
         is administered according to standard guidelines. (See
         <a class="medical medical_review" href="/z/d/html/6796.html" rel="external">
          "Antenatal corticosteroid therapy for reduction of neonatal respiratory morbidity and mortality from preterm delivery"
         </a>
         .)
        </p>
        <p>
         Most women with no bleeding, contractions, or rupture of membranes remain stable through 36 weeks of gestation [
         <a href="#rid15">
          15
         </a>
         ]. For those who become unstable between 34 and 36 weeks, outcomes with emergency delivery still appear to be favorable in centers of excellence [
         <a href="#rid21">
          21
         </a>
         ]. Therefore, we individualize timing of planned delivery within this interval based on clinical symptoms, obstetric history (eg, prior preterm birth), cervical length, and logistical considerations (eg, distance from a center of excellence). Delivery beyond 36 weeks is not advised because the favorable effects of expectant management on fetal maturation at this gestational age decrease and are small compared with the increasing and substantial maternal risk if labor leads to hemorrhage.
        </p>
        <p>
         This approach is supported by studies reporting favorable outcomes at 34 to 35 weeks of gestation, as well as a decision analysis concluding that 34 weeks' gestation is optimal [
         <a href="#rid8">
          8,12,49
         </a>
         ]. The Society for Maternal-Fetal Medicine recommends delivery between 34 and 37 weeks of gestation for stable women with placenta accreta [
         <a href="#rid48">
          48
         </a>
         ]. An international panel suggested delivery at ≥36+0 weeks in asymptomatic women (eg, no bleeding, rupture of membranes, or preterm labor) and no history of preterm birth [
         <a href="#rid4">
          4
         </a>
         ]. They suggested delivery at around 34+0 weeks in women with a previous preterm birth, multiple episodes of minor bleeding, or a single episode of substantial bleeding. As discussed above, the authors favor aiming for delivery closer to 34 weeks of gestation (rather than 36 weeks) in most cases, although the optimal timing of delivery remains controversial and individualized management is appropriate.
        </p>
        <p class="headingAnchor" id="H1822805821">
         <span class="h2">
          Procedure
         </span>
        </p>
        <p class="headingAnchor" id="H1320730">
         <span class="h3">
          Cesarean hysterectomy
         </span>
         <span class="headingEndMark">
          —
         </span>
         We typically make a vertical midline skin incision or a Cherney incision  (
         <a class="graphic graphic_figure graphicRef73105" href="/z/d/graphic/73105.html" rel="external">
          figure 1
         </a>
         ); however, others may choose to make a transverse incision (eg, Pfannenstiel) in cases with a low likelihood of intraoperative complications (eg, posterior placenta not extending to the serosa) [
         <a href="#rid4">
          4
         </a>
         ]. The pelvis is inspected for signs of percreta and the location of any collateral blood supply before proceeding with the uterine incision.
        </p>
        <p>
         An intraoperative ultrasound examination may be useful to map the placental edge and determine the best position for the hysterotomy incision, which should avoid transecting the placenta. We make a vertical hysterotomy at least two fingerbreadths above the placental edge; leaving a myometrial margin between the placenta and incision helps to prevent disruption of the placenta during opening or closing of the uterus. In cases in which a placenta accreta has been disturbed at delivery and is hemorrhaging, conservative measures are rarely effective and endanger the patient by delaying performance of hysterectomy. During the delay, massive hemorrhage can lead to a downward spiral characterized by hypoperfusion of all organ systems, hypothermia, coagulopathy, and metabolic acidosis. (See
         <a class="local">
          'Unexpected placenta accreta'
         </a>
         below.)
        </p>
        <p>
         After delivery of the infant, the cord is cut, the uterine incision is rapidly closed to decrease blood loss, and hysterectomy is performed. Even in the absence of extrauterine involvement by a percreta, the procedure is often difficult because of extensive parametrial vascular engorgement and friable tissues. Management of peripartum hysterectomy is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/5395.html" rel="external">
          "Peripartum hysterectomy for management of hemorrhage"
         </a>
         .)
        </p>
        <p>
         Prophylactic
         <a class="drug drug_general" data-topicid="9734" href="/z/d/drug information/9734.html" rel="external">
          oxytocin
         </a>
         is not routinely administered after the infant is delivered because it may lead to partial placental separation and, in turn, increased bleeding [
         <a href="#rid4">
          4
         </a>
         ]. However, if the placenta has been mostly or completely removed or bleeding is already heavy, then uterotonic drugs should be given. Management of postpartum hemorrhage is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/6712.html" rel="external">
          "Postpartum hemorrhage: Management approaches requiring laparotomy"
         </a>
         .)
        </p>
        <p>
         We avoid internal iliac (hypogastric) artery ligation because it is time consuming, operator dependent, ineffective (without hysterectomy) for controlling pelvic hemorrhage in up to 60 percent of cases [
         <a href="#rid50">
          50-52
         </a>
         ], and precludes use of selective pelvic angiography and embolization if needed subsequently. (See
         <a class="medical medical_review" href="/z/d/html/3302.html" rel="external">
          "Management of hemorrhage in gynecologic surgery", section on 'Internal iliac artery ligation'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1320737">
         <span class="h3">
          Management of placenta percreta with bladder invasion
         </span>
         <span class="headingEndMark">
          —
         </span>
         Placenta percreta with bladder invasion may require partial cystectomy. In one review of 54 cases of placenta percreta invading the bladder, partial cystectomy was performed in 24 of the 54 patients (44 percent) [
         <a href="#rid53">
          53
         </a>
         ]. Ideally, a urogynecologist, urologist, or gynecologic oncologist should be consulted when the bladder is involved. Cystoscopy or intentional cystotomy at surgery is often helpful for assessing the degree of bladder, and possible ureteral, involvement [
         <a href="#rid54">
          54
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H864200370">
         <span class="h1">
          CONSERVATIVE MANAGEMENT OF PLACENTA ACCRETA
         </span>
        </p>
        <p class="headingAnchor" id="H3200420093">
         <span class="h2">
          Potential candidates
         </span>
         <span class="headingEndMark">
          —
         </span>
         Uterine conservation may be considered in:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients who very much want to preserve fertility. Such patients should be counseled extensively regarding the risks of hemorrhage, infection, possible need for intra- or postoperative lifesaving hysterectomy, and even death, as well as suboptimal outcomes (including recurrence or hemorrhage [
         <a href="#rid55">
          55,56
         </a>
         ]) in future pregnancies.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         When hysterectomy is thought to have an unacceptably high risk of hemorrhage or injury to other organs, which may be mitigated by leaving the placenta in situ [
         <a href="#rid57">
          57
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         When placental resection is thought to be possible because of focal accreta or a fundal or posterior placenta. (See
         <a class="local">
          'Uterine conservation with placental resection'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1320780">
         <span class="h2">
          Uterine conservation with the placenta left in situ
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Expectant management
         </strong>
         – In this approach, the placenta is left in situ
         <em>
         </em>
         after delivery of the newborn. The umbilical cord is ligated at its placental insertion site; the hysterotomy is closed in the standard way; and uterotonic drugs, compression sutures, intrauterine balloon tamponade [or, rarely, intrauterine vacuum-induced compression], uterine artery embolization, and/or uterine artery ligation are variably used. In some cases, this is done prophylactically and in others as needed to manage postpartum hemorrhage [
         <a href="#rid4">
          4,58
         </a>
         ]. The committee opinion of the American College of Obstetricians and Gynecologists indicates that this approach should be attempted only rarely or as part of an approved clinical trial in fully informed patients [
         <a href="#rid4">
          4
         </a>
         ]. However, this approach is gaining popularity as it may be less morbid than cesarean hysterectomy [
         <a href="#rid59">
          59
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Delayed hysteroscopic resection of placental remnants has been used successfully to expedite resolution of the placenta or treat delayed bleeding and/or pelvic pain if resolution is incomplete, but experience is limited [
         <a href="#rid60">
          60-62
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Delayed-interval hysterectomy
         </strong>
         – Delayed-interval hysterectomy is another option, particularly for patients with placenta percreta, but experience is limited [
         <a href="#rid63">
          63-65
         </a>
         ] and experts have recommended against it [
         <a href="#rid4">
          4
         </a>
         ]. Clinicians experienced with the technique have suggested it as an option for only the most severe, potentially life-threatening cases of placenta percreta or when immediate hysterectomy is too dangerous because of the extent of placental invasion or lack of appropriate resources [
         <a href="#rid65">
          65
         </a>
         ]. Hysterectomy is delayed until four to six weeks postpartum. Experience with this approach has yielded mixed results, and no high-quality data regarding the advantages and disadvantages compared with planned cesarean hysterectomy exist.
        </p>
        <p>
        </p>
        <p>
         Adjunctive therapy with
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         therapy should
         <strong>
          not
         </strong>
         be used: There is no convincing evidence that it improves any outcome when the placenta is left in situ, and there is clear evidence of drug-related harms (eg, pancytopenia, nephrotoxicity) [
         <a href="#rid4">
          4
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H538256329">
         <span class="h3">
          Complications
         </span>
         <span class="headingEndMark">
          —
         </span>
         The prolonged course and significant risks of uterine conservation with the placenta left in situ were illustrated by a systematic review of 10 cohort studies and 50 case series or case reports describing 434 patients with PAS managed conservatively (eg, expectant management, uterine artery embolization,
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         therapy, hemostatic sutures, arterial ligation, balloon tamponade) [
         <a href="#rid66">
          66
         </a>
         ]. The following short-term outcomes were reported, but data were not available for all outcomes in all studies:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Severe vaginal bleeding: 53 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Sepsis: 6 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Secondary hysterectomy: 19 percent (range 6 to 31 percent)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Death: 0.3 percent (range 0 to 4 percent)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Subsequent pregnancy: 67 percent (range 15 to 73 percent)
        </p>
        <p>
        </p>
        <p>
         In the largest study, which included 167 women with placenta accreta managed conservatively using a variety of modalities [
         <a href="#rid53">
          53
         </a>
         ], 131 women (78 percent) retained their uterus, 18 women required hysterectomy within 24 hours of delivery because of hemorrhage, and 18 women underwent hysterectomy because of complications at a median 39 days after delivery (range 9 to 105 days). Ten women experienced severe morbidity, including sepsis, vesicouterine fistula, and/or uterine necrosis. In women who retained their uterus, placental resorption was observed on follow-up at a median of 13.5 weeks (range 4 to 60 weeks). However, 25 percent of these women underwent hysteroscopy, curettage, or both to remove retained placental tissue at a median of 20 weeks postpartum (range 2 to 45 weeks).
        </p>
        <p>
         Subsequently, a population-based study in France (PACCRETA) compared outcomes in 86 PAS cases managed conservatively (no planned hysterectomy) with 62 managed by cesarean hysterectomy [
         <a href="#rid59">
          59
         </a>
         ]. Conservative management was associated with less need for transfusion of more than four units of blood (16.3 versus 59 percent; risk ratio in propensity score weighted model 0.29, 95% CI 0.19-0.45) and similar or lower rates of other morbidities. However, these results are not generalizable to centers where multidisciplinary care is common and has led to reduced morbidity and mortality for PAS (only 19 percent of patients in PACCRETA had this care) [
         <a href="#rid67">
          67
         </a>
         ]. In addition, the PACCRETA surgeons attempted placental removal in most hysterectomy cases, whereas most clinicians would avoid any attempt to separate the placenta because it increases blood loss.
        </p>
        <p>
         Long-term reproductive outcomes following conservative management appear to be suboptimal, but data are limited [
         <a href="#rid68">
          68-70
         </a>
         ]. Although there appears to be an increased risk of developing intrauterine synechiae, most women who desire another pregnancy can conceive and are at increased risk of recurrent placenta accreta. This is expected since the underlying abnormality of the endometrium has not been corrected and can be worsened by postpartum curettage. A retrospective multicenter study of 96 women with a history of conservative management of placenta accreta (ie, uterine preservation) observed that eight had severe intrauterine synechiae and were amenorrheic [
         <a href="#rid69">
          69
         </a>
         ]. In three cases series with 9, 21, and 30 deliveries after conservative management of placenta accreta, recurrent placenta accreta was noted in 12 of the 60 subsequent deliveries (20 percent, range 13 to 29 percent) [
         <a href="#rid68">
          68,69,71
         </a>
         ].
        </p>
        <p>
         Another consideration is that it is not possible to be certain that women undergoing conservative management truly had PAS since they did not have histologic confirmation after hysterectomy. These women may comprise a different population at less risk for serious bleeding than women requiring hysterectomy. For example, cases of an abnormally adherent placenta managed conservatively had lower rates of prior cesarean delivery and previa than those managed with hysterectomy [
         <a href="#rid7">
          7,8,12,53
         </a>
         ]. Accordingly, the relative merits of conservative management compared with planned cesarean hysterectomy remain an important knowledge gap that should be addressed with additional research and clinical trials.
        </p>
        <p class="headingAnchor" id="H1822804163">
         <span class="h2">
          Uterine conservation with placental resection
         </span>
         <span class="headingEndMark">
          —
         </span>
         Uterine conservation with placental resection may be successful without excessive risk in two clinical settings:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Focal accreta
         </strong>
         – Focal accreta may be suspected based on imaging findings antepartum or detected intrapartum because of hemorrhage and/or a partially retained placenta at delivery. There are a few reports describing cases of successful uterine conservation in these cases [
         <a href="#rid54">
          54-56
         </a>
         ]. Potential candidates for this approach are women with a clearly delineated focal area of PAS (adherent area &lt;50 percent of the anterior surface of the uterus [
         <a href="#rid4">
          4
         </a>
         ]) and an accessible border of healthy myometrium [
         <a href="#rid58">
          58
         </a>
         ]. Desire for future pregnancy is not necessarily a factor as the procedure is likely to be less morbid than the alternative cesarean hysterectomy, although morbidity of focal-occult PAS was similar to those with previa-associated accreta in one study [
         <a href="#rid72">
          72
         </a>
         ]. Management involves oversewing the bleeding sites or removing a small wedge of uterine tissue containing the focally adherent placenta (placental-myometrial en bloc excision and repair).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Fundal or posterior placenta accreta
         </strong>
         – In contrast to anterior placenta accreta, the authors' experience is that uterine conservation may be possible for a posterior or fundal accreta, since bleeding after removal of placenta accreta in these locations is more readily controlled medically, with interventional radiology, and with conservative surgery. The option for a (relatively) easy hysterectomy is still available if bleeding cannot be adequately controlled by these other measures.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Triple P procedure
         </strong>
         – Another approach to uterine conservation with placental resection is the triple P procedure [
         <a href="#rid57">
          57,73
         </a>
         ]. This involves perioperative localization of the upper placental edge (the fetus is delivered at this level), uterine devascularization by temporary occlusive balloons in the anterior division of the internal iliac arteries, placental nonseparation, and myometrial excision of the affected area followed by the repair of the myometrial defect. It has only been reported in a small number of cases; data on efficacy, safety, and long-term outcome are very limited.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4018243426">
         <span class="h2">
          Recurrence in future pregnancies
         </span>
         <span class="headingEndMark">
          —
         </span>
         In two retrospective cohort studies, PAS occurred in 22 and 29 percent of future pregnancies of women successfully managed conservatively [
         <a href="#rid68">
          68,69
         </a>
         ]. Women who choose to become pregnant again should be aware of this risk and consult with a maternal-fetal medicine specialist early in pregnancy to facilitate diagnosis and management.
        </p>
        <p class="headingAnchor" id="H864461153">
         <span class="h1">
          UNEXPECTED PLACENTA ACCRETA
         </span>
        </p>
        <p class="headingAnchor" id="H3688459856">
         <span class="h2">
          At cesarean delivery
         </span>
         <span class="headingEndMark">
          —
         </span>
         Some cases of placenta accreta are first recognized at cesarean delivery, typically repeat cesarean delivery. Upon entering the peritoneal cavity, the surgeon may make the diagnosis of PAS if one or more of the following are seen:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Placental tissue invading the lower uterine segment, serosa, or bladder.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Increased and tortuous vascularity along the serosa of the lower uterine segment. Vessels may run cranio-caudally in the peritoneum.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A bluish/purple and markedly distended lower uterine segment bulging toward the pelvic sidewalls.
        </p>
        <p>
        </p>
        <p>
         It is important to distinguish these findings from a placenta normally attached underneath a uterine window (uterine scar dehiscence). In these cases, the uterine tissue and vessels appear normal.
        </p>
        <p>
         After delivery of the infant, PAS is suggested if light traction on the umbilical cord pulls the uterine wall inward, without placental separation, and the uterus apart from the placental bed contracts. If the diagnosis is uncertain, then gentle digital exploration for plane of cleavage can be attempted; the absence of a plane is diagnostic.
        </p>
        <p class="headingAnchor" id="H1240979409">
         <span class="h3">
          Management
         </span>
         <span class="headingEndMark">
          —
         </span>
         If PAS is suspected before the hysterotomy, it is important to avoid or minimize manipulation of the uterus or sites of possible extrauterine placental extension (eg, the posterior bladder wall) as this can precipitate life-threatening hemorrhage. We agree with an expert review that suggested the following approach when the fetus has not been delivered [
         <a href="#rid1">
          1
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If the patient is not bleeding heavily, mother and fetus are stable, and resources for managing these complicated cases are not immediately available, the uterus can be covered with warm packs and further surgery delayed until appropriate personnel and other resources are available.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If the patient is not bleeding heavily, mother and fetus are stable, and assembling these resources is not possible locally, the abdomen should be closed and the patient expeditiously transferred to a facility that can manage these patients, although the risk of massive hemorrhage in transit must be considered.
        </p>
        <p>
        </p>
        <p>
         If the mother is bleeding heavily and/or the fetus is compromised, the best option is delivery through a hysterotomy far from the placenta, followed by closure of the hysterotomy with the placenta left undisturbed until appropriate personnel and resources for maternal care are available. Intraoperative ultrasound using a probe with a sterile cover can indicate the placental location. If there is no time for ultrasound examination, in most cases, a hysterotomy in the posterior uterus or fundus will avoid the placenta.
        </p>
        <p>
         Women who are bleeding heavily or otherwise unstable need to be managed as optimally as allowed by the clinical setting and available resources. This includes resuscitation with fluid and blood products, standard surgical procedures for controlling hemorrhage, and pressure on bleeding sites (eg, digital, abdominopelvic packs); infrarenal aortic compression or aortic cross-clamping can be used in an attempt to control life-threatening hemorrhage. Direct pressure on a percreta should be avoided or applied cautiously as it may increase the size of the bleeding area. A massive transfusion protocol is useful  (
         <a class="graphic graphic_algorithm graphicRef91236" href="/z/d/graphic/91236.html" rel="external">
          algorithm 1
         </a>
         ).
        </p>
        <p>
         Intraoperative management of women with massive hemorrhage at cesarean delivery is discussed in detail separately. Key principles include: keeping the patient warm, rapidly transfusing red cells to restore or maintain adequate circulatory volume and tissue oxygenation, reversing or preventing coagulopathy by administering fresh frozen plasma and platelets (eg, 1:1:1 or 1:2:4 ratio of packed red blood cells, fresh frozen plasma, and platelets), and reversing electrolyte imbalance, especially hypocalcemia [
         <a href="#rid2">
          2,74
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6712.html" rel="external">
          "Postpartum hemorrhage: Management approaches requiring laparotomy"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1826165705">
         <span class="h2">
          At vaginal delivery
         </span>
         <span class="headingEndMark">
          —
         </span>
         Rarely, a focal or complete placenta accreta is first recognized at the time of manual removal of a retained placenta after vaginal delivery. In these cases, there is no plane of cleavage between the myometrium and either the entire placenta or focal areas of the placenta. Life-threatening hemorrhage may occur. These patients should receive fluids and transfusion, as appropriate, while being prepared for laparotomy and surgical management (hysterectomy of focal resection), as described above.
        </p>
        <p class="headingAnchor" id="H864460986">
         <span class="h1">
          POSTOPERATIVE CARE
         </span>
         <span class="headingEndMark">
          —
         </span>
         An intensive care unit bed should be available for postoperative care, if needed. These patients may require ventilator support due to pulmonary edema from massive fluid resuscitation or fluid shifts, or from acute transfusion-related lung injury [
         <a href="#rid1">
          1
         </a>
         ]. Some patients need vasopressor support and invasive hemodynamic monitoring. Postoperative bleeding may occur, and the availability of interventional radiology to provide angiographic embolization of deep pelvic vessels, thus avoiding reoperation, can safely enhance patient care. (See
         <a class="medical medical_review" href="/z/d/html/1629.html" rel="external">
          "Critical illness during pregnancy and the peripartum period"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3532980993">
         <span class="h1">
          SECOND-TRIMESTER PREGNANCY TERMINATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/14194.html" rel="external">
          "Overview of second-trimester pregnancy termination", section on 'Placental abnormalities'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2059431344">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/118733.html" rel="external">
          "Society guideline links: Obstetric hemorrhage"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1320787">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Preoperative preparation
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Planning and personnel
         </strong>
         – It is critical to develop a plan preoperatively for managing women with a high likelihood of placenta accreta spectrum (PAS). The plan should involve a multidisciplinary team and scheduled delivery in a facility with resources and personnel to manage massive hemorrhage and complicated pelvic surgery.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         If the clinician does not manage patients with PAS routinely, these patients should be referred to a center with experience and expertise. (See
         <a class="local">
          'Components of preoperative planning'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Antenatal corticosteroids
         </strong>
         are administered according to standard guidelines. (See
         <a class="medical medical_review" href="/z/d/html/6796.html" rel="external">
          "Antenatal corticosteroid therapy for reduction of neonatal respiratory morbidity and mortality from preterm delivery"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Prophylactic ureteral stent placement
         </strong>
         – Although of unproven efficacy, we use ureteral stents routinely when feasible to reduce the risk of genitourinary injury. (See
         <a class="local">
          'Components of preoperative planning'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Prophylactic endovascular intervention
         </strong>
         with a balloon catheter or arterial embolization, if available, may be used to decrease hemorrhage during or after deliveries of pregnancies with abnormal placental implantation, but efficacy is uncertain, and complications may occur. (See
         <a class="local">
          'Endovascular intervention for hemorrhage control'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Planned cesarean hysterectomy
         </strong>
         – Given the risks of massive hemorrhage during attempted placental removal if accreta is present, we believe that recommending a cesarean hysterectomy based on imaging findings is the most reasonable and safest approach to management. (See
         <a class="local">
          'Delivery'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In rare situations, uterine conservation may be attempted if future childbearing is desired and after extensive counseling regarding risks. (See
         <a class="local">
          'Conservative management of placenta accreta'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Delivery timing
         </strong>
         – Our approach is to plan delivery between 34+0 and 35+6 weeks of gestation in stable patients. Delivery sooner is appropriate in the setting of bleeding, labor, rupture of membranes, or other standard obstetric indications for delivery. We schedule the procedure at a facility with personnel experienced in managing pelvic hemorrhage and its complications. (See
         <a class="local">
          'Delivery'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Management of the placenta
         </strong>
         – In most patients, we suggest leaving the placenta undisturbed in situ (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'Procedure'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Uterine conservation with placental resection may be successful without excessive risk in selected cases of focal accreta or a posterior or fundal accreta. (See
         <a class="local">
          'Uterine conservation with placental resection'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2613692921">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Robert Resnik, MD, who contributed to an earlier version of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Silver RM, Fox KA, Barton JR, et al. Center of excellence for placenta accreta. Am J Obstet Gynecol 2015; 212:561.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           American College of Obstetricians and Gynecologists, Society for Maternal-Fetal Medicine. Obstetric Care Consensus No. 7: Placenta Accreta Spectrum. Obstet Gynecol 2018; 132:e259.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Han X, Guo Z, Yang X, et al. Association of Placenta Previa With Severe Maternal Morbidity Among Patients With Placenta Accreta Spectrum Disorder. JAMA Netw Open 2022; 5:e2228002.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Collins SL, Alemdar B, van Beekhuizen HJ, et al. Evidence-based guidelines for the management of abnormally invasive placenta: recommendations from the International Society for Abnormally Invasive Placenta. Am J Obstet Gynecol 2019; 220:511.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Merrill J, Sultan P, Sharawi N. Advances in anesthetic and obstetric management of patients with placenta accreta spectrum. Curr Opin Anaesthesiol 2021; 34:260.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Publications Committee, Society for Maternal-Fetal Medicine, Belfort MA. Placenta accreta. Am J Obstet Gynecol 2010; 203:430.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eller AG, Bennett MA, Sharshiner M, et al. Maternal morbidity in cases of placenta accreta managed by a multidisciplinary care team compared with standard obstetric care. Obstet Gynecol 2011; 117:331.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shamshirsaz AA, Fox KA, Salmanian B, et al. Maternal morbidity in patients with morbidly adherent placenta treated with and without a standardized multidisciplinary approach. Am J Obstet Gynecol 2015; 212:218.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bartels HC, Rogers AC, O'Brien D, et al. Association of Implementing a Multidisciplinary Team Approach in the Management of Morbidly Adherent Placenta With Maternal Morbidity and Mortality. Obstet Gynecol 2018; 132:1167.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schwickert A, van Beekhuizen HJ, Bertholdt C, et al. Association of peripartum management and high maternal blood loss at cesarean delivery for placenta accreta spectrum (PAS): A multinational database study. Acta Obstet Gynecol Scand 2021; 100 Suppl 1:29.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eller AG, Porter TF, Soisson P, Silver RM. Optimal management strategies for placenta accreta. BJOG 2009; 116:648.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Warshak CR, Ramos GA, Eskander R, et al. Effect of predelivery diagnosis in 99 consecutive cases of placenta accreta. Obstet Gynecol 2010; 115:65.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tikkanen M, Paavonen J, Loukovaara M, Stefanovic V. Antenatal diagnosis of placenta accreta leads to reduced blood loss. Acta Obstet Gynecol Scand 2011; 90:1140.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grosvenor A, Silver R, Porter TF, Zempolich K. Optimal management of placenta accreta. Am J Obstet Gynecol 2007; 195:S82.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bowman ZS, Manuck TA, Eller AG, et al. Risk factors for unscheduled delivery in patients with placenta accreta. Am J Obstet Gynecol 2014; 210:241.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shamshirsaz AA, Fox KA, Erfani H, et al. Outcomes of Planned Compared With Urgent Deliveries Using a Multidisciplinary Team Approach for Morbidly Adherent Placenta. Obstet Gynecol 2018; 131:234.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sadashivaiah J, Wilson R, Thein A, et al. Role of prophylactic uterine artery balloon catheters in the management of women with suspected placenta accreta. Int J Obstet Anesth 2011; 20:282.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oyelese Y, Smulian JC. Placenta previa, placenta accreta, and vasa previa. Obstet Gynecol 2006; 107:927.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wong HS, Hutton J, Zuccollo J, et al. The maternal outcome in placenta accreta: the significance of antenatal diagnosis and non-separation of placenta at delivery. N Z Med J 2008; 121:30.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Einerson BD, Weiniger CF. Placenta accreta spectrum disorder: updates on anesthetic and surgical management strategies. Int J Obstet Anesth 2021; 46:102975.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pri-Paz S, Fuchs KM, Gaddipati S, et al. Comparison between emergent and elective delivery in women with placenta accreta. J Matern Fetal Neonatal Med 2013; 26:1007.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wright JD, Pri-Paz S, Herzog TJ, et al. Predictors of massive blood loss in women with placenta accreta. Am J Obstet Gynecol 2011; 205:38.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miller SE, Leonard SA, Meza PK, et al. Red Blood Cell Transfusion in Patients With Placenta Accreta Spectrum: A Systematic Review and Meta-analysis. Obstet Gynecol 2023; 141:49.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Erfani H, Salmanian B, Fox KA, et al. Urologic morbidity associated with placenta accreta spectrum surgeries: single-center experience with a multidisciplinary team. Am J Obstet Gynecol 2022; 226:245.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lucidi A, Jauniaux E, Hussein AM, et al. Urological complications in women undergoing Cesarean section for placenta accreta spectrum disorders: systematic review and meta-analysis. Ultrasound Obstet Gynecol 2023; 62:633.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Scaglione MA, Allshouse AA, Canfield DR, et al. Prophylactic Ureteral Stent Placement and Urinary Injury During Hysterectomy for Placenta Accreta Spectrum. Obstet Gynecol 2022; 140:806.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Horgan R, Hessami K, Hage Diab Y, et al. Prophylactic ureteral stent placement for the prevention of genitourinary tract injury during hysterectomy for placenta accreta spectrum: systematic review and meta-analysis. Am J Obstet Gynecol MFM 2023; 5:101120.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bishop S, Butler K, Monaghan S, et al. Multiple complications following the use of prophylactic internal iliac artery balloon catheterisation in a patient with placenta percreta. Int J Obstet Anesth 2011; 20:70.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lilker SJ, Meyer RA, Downey KN, Macarthur AJ. Anesthetic considerations for placenta accreta. Int J Obstet Anesth 2011; 20:288.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Taylor NJ, Russell R. Anaesthesia for abnormally invasive placenta: a single-institution case series. Int J Obstet Anesth 2017; 30:10.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           D'Antonio F, Iacovelli A, Liberati M, et al. Role of interventional radiology in pregnancy complicated by placenta accreta spectrum disorder: systematic review and meta-analysis. Ultrasound Obstet Gynecol 2019; 53:743.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee AY, Ballah D, Morena I, et al. Outcomes of balloon occlusion in the University of California Morbidly Adherent Placenta Registry. Am J Obstet Gynecol MFM 2019.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Li Z, Chen Y, Zeng X, et al. Clinical and hemodynamic insights into the use of internal iliac artery balloon occlusion as a prophylactic technique for treating postpartum hemorrhage. J Biomech 2021; 129:110827.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ojala K, Perälä J, Kariniemi J, et al. Arterial embolization and prophylactic catheterization for the treatment for severe obstetric hemorrhage*. Acta Obstet Gynecol Scand 2005; 84:1075.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shrivastava V, Nageotte M, Major C, et al. Case-control comparison of cesarean hysterectomy with and without prophylactic placement of intravascular balloon catheters for placenta accreta. Am J Obstet Gynecol 2007; 197:402.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sewell MF, Rosenblum D, Ehrenberg H. Arterial embolus during common iliac balloon catheterization at cesarean hysterectomy. Obstet Gynecol 2006; 108:746.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arora N, Matheny ME, Sepke C, Resnic FS. A propensity analysis of the risk of vascular complications after cardiac catheterization procedures with the use of vascular closure devices. Am Heart J 2007; 153:606.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barth WH Jr, Kwolek CJ, Abrams JL, et al. Case records of the Massachusetts General Hospital. Case 23-2011. A 40-year-old pregnant woman with placenta accreta who declined blood products. N Engl J Med 2011; 365:359.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Angstmann T, Gard G, Harrington T, et al. Surgical management of placenta accreta: a cohort series and suggested approach. Am J Obstet Gynecol 2010; 202:38.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ordoñez CA, Manzano-Nunez R, Parra MW, et al. Prophylactic use of resuscitative endovascular balloon occlusion of the aorta in women with abnormal placentation: A systematic review, meta-analysis, and case series. J Trauma Acute Care Surg 2018; 84:809.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Okada A, Nakamoto O, Komori M, et al. Resuscitative endovascular balloon occlusion of the aorta as an adjunct for hemorrhagic shock due to uterine rupture: a case report. Clin Case Rep 2017; 5:1565.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stensaeth KH, Sovik E, Haig IN, et al. Fluoroscopy-free Resuscitative Endovascular Balloon Occlusion of the Aorta (REBOA) for controlling life threatening postpartum hemorrhage. PLoS One 2017; 12:e0174520.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shoji T, Tarui T, Igarashi T, et al. Resuscitative Endovascular Balloon Occlusion of the Aorta Using a Low-Profile Device is Easy and Safe for Emergency Physicians in Cases of Life-Threatening Hemorrhage. J Emerg Med 2018; 54:410.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Morrison JJ, Galgon RE, Jansen JO, et al. A systematic review of the use of resuscitative endovascular balloon occlusion of the aorta in the management of hemorrhagic shock. J Trauma Acute Care Surg 2016; 80:324.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Manzano-Nunez R, Escobar-Vidarte MF, Orlas CP, et al. Resuscitative endovascular balloon occlusion of the aorta deployed by acute care surgeons in patients with morbidly adherent placenta: a feasible solution for two lives in peril. World J Emerg Surg 2018; 13:44.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Whittington JR, Pagan ME, Sharawi N, et al. REBOA placement for placenta accreta spectrum: patient selection and utilization. J Matern Fetal Neonatal Med 2022; 35:6440.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nieto-Calvache AJ, Hidalgo-Cardona A, Lopez-Girón MC, et al. Arterial thrombosis after REBOA use in placenta accreta spectrum: a case series. J Matern Fetal Neonatal Med 2022; 35:4031.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Society for Maternal-Fetal Medicine (SMFM). Electronic address:
           <span class="__cf_email__" data-cfemail="d8a8adbaab98abb5beb5f6b7aabf">
            [email protected]
           </span>
           , Gyamfi-Bannerman C. Society for Maternal-Fetal Medicine (SMFM) Consult Series #44: Management of bleeding in the late preterm period. Am J Obstet Gynecol 2018; 218:B2.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Robinson BK, Grobman WA. Effectiveness of timing strategies for delivery of individuals with placenta previa and accreta. Obstet Gynecol 2010; 116:835.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Clark SL, Phelan JP, Yeh SY, et al. Hypogastric artery ligation for obstetric hemorrhage. Obstet Gynecol 1985; 66:353.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Papp Z, Tóth-Pál E, Papp C, et al. Hypogastric artery ligation for intractable pelvic hemorrhage. Int J Gynaecol Obstet 2006; 92:27.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Unal O, Kars B, Buyukbayrak EE, et al. The effectiveness of bilateral hypogastric artery ligation for obstetric hemorrhage in three different underlying conditions and its impact on future fertility. J Matern Fetal Neonatal Med 2011; 24:1273.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sentilhes L, Ambroselli C, Kayem G, et al. Maternal outcome after conservative treatment of placenta accreta. Obstet Gynecol 2010; 115:526.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Palacios Jaraquemada JM, Pesaresi M, Nassif JC, Hermosid S. Anterior placenta percreta: surgical approach, hemostasis and uterine repair. Acta Obstet Gynecol Scand 2004; 83:738.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chandraharan E, Rao S, Belli AM, Arulkumaran S. The Triple-P procedure as a conservative surgical alternative to peripartum hysterectomy for placenta percreta. Int J Gynaecol Obstet 2012; 117:191.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Clausen C, Lönn L, Langhoff-Roos J. Management of placenta percreta: a review of published cases. Acta Obstet Gynecol Scand 2014; 93:138.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Teixidor Viñas M, Belli AM, Arulkumaran S, Chandraharan E. Prevention of postpartum hemorrhage and hysterectomy in patients with morbidly adherent placenta: a cohort study comparing outcomes before and after introduction of the Triple-P procedure. Ultrasound Obstet Gynecol 2015; 46:350.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fox KA, Shamshirsaz AA, Carusi D, et al. Conservative management of morbidly adherent placenta: expert review. Am J Obstet Gynecol 2015; 213:755.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sentilhes L, Seco A, Azria E, et al. Conservative management or cesarean hysterectomy for placenta accreta spectrum: the PACCRETA prospective study. Am J Obstet Gynecol 2022; 226:839.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Legendre G, Zoulovits FJ, Kinn J, et al. Conservative management of placenta accreta: hysteroscopic resection of retained tissues. J Minim Invasive Gynecol 2014; 21:910.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hequet D, Morel O, Soyer P, et al. Delayed hysteroscopic resection of retained tissues and uterine conservation after conservative treatment for placenta accreta. Aust N Z J Obstet Gynaecol 2013; 53:580.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rein DT, Schmidt T, Hess AP, et al. Hysteroscopic management of residual trophoblastic tissue is superior to ultrasound-guided curettage. J Minim Invasive Gynecol 2011; 18:774.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rupley DM, Tergas AI, Palmerola KL, Burke WM. Robotically assisted delayed total laparoscopic hysterectomy for placenta percreta. Gynecol Oncol Rep 2016; 17:53.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee PS, Kempner S, Miller M, et al. Multidisciplinary approach to manage antenatally suspected placenta percreta: updated algorithm and patient outcomes. Gynecol Oncol Res Pract 2017; 4:11.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zuckerwise LC, Craig AM, Newton JM, et al. Outcomes following a clinical algorithm allowing for delayed hysterectomy in the management of severe placenta accreta spectrum. Am J Obstet Gynecol 2020; 222:179.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Steins Bisschop CN, Schaap TP, Vogelvang TE, Scholten PC. Invasive placentation and uterus preserving treatment modalities: a systematic review. Arch Gynecol Obstet 2011; 284:491.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shainker SA, Zuckerwise LC, Shamshirsaz AA. Conservative management of placenta accreta spectrum: is it time? Am J Obstet Gynecol 2022; 226:871.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Provansal M, Courbiere B, Agostini A, et al. Fertility and obstetric outcome after conservative management of placenta accreta. Int J Gynaecol Obstet 2010; 109:147.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sentilhes L, Kayem G, Ambroselli C, et al. Fertility and pregnancy outcomes following conservative treatment for placenta accreta. Hum Reprod 2010; 25:2803.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Amsalem H, Kingdom JC, Farine D, et al. Planned caesarean hysterectomy versus "conserving" caesarean section in patients with placenta accreta. J Obstet Gynaecol Can 2011; 33:1005.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eshkoli T, Weintraub AY, Sergienko R, Sheiner E. Placenta accreta: risk factors, perinatal outcomes, and consequences for subsequent births. Am J Obstet Gynecol 2013; 208:219.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Larish A, Horst K, Brunton J, et al. Focal-occult placenta accreta: a clandestine source of maternal morbidity. Am J Obstet Gynecol MFM 2023; 5:100924.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Piñas-Carrillo A, Chandraharan E. Conservative surgical approach: The Triple P procedure. Best Pract Res Clin Obstet Gynaecol 2021; 72:67.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Erfani H, Shamshirsaz AA, Fox KA, et al. Severe hypocalcemia during surgery for placenta accreta spectrum: The case for empiric replacement. Acta Obstet Gynecol Scand 2019; 98:1326.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 83129 Version 66.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25460838" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Center of excellence for placenta accreta.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30461695" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Obstetric Care Consensus No. 7: Placenta Accreta Spectrum.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35994286" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Association of Placenta Previa With Severe Maternal Morbidity Among Patients With Placenta Accreta Spectrum Disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30849356" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Evidence-based guidelines for the management of abnormally invasive placenta: recommendations from the International Society for Abnormally Invasive Placenta.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33935172" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Advances in anesthetic and obstetric management of patients with placenta accreta spectrum.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21055510" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Placenta accreta.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21309195" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Maternal morbidity in cases of placenta accreta managed by a multidisciplinary care team compared with standard obstetric care.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25173187" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Maternal morbidity in patients with morbidly adherent placenta treated with and without a standardized multidisciplinary approach.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30234729" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Association of Implementing a Multidisciplinary Team Approach in the Management of Morbidly Adherent Placenta With Maternal Morbidity and Mortality.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33524163" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Association of peripartum management and high maternal blood loss at cesarean delivery for placenta accreta spectrum (PAS): A multinational database study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19191778" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Optimal management strategies for placenta accreta.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20027036" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Effect of predelivery diagnosis in 99 consecutive cases of placenta accreta.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21488840" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Antenatal diagnosis of placenta accreta leads to reduced blood loss.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Optimal management of placenta accreta
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24096181" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Risk factors for unscheduled delivery in patients with placenta accreta.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29324609" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Outcomes of Planned Compared With Urgent Deliveries Using a Multidisciplinary Team Approach for Morbidly Adherent Placenta.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21852107" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Role of prophylactic uterine artery balloon catheters in the management of women with suspected placenta accreta.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16582134" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Placenta previa, placenta accreta, and vasa previa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18677328" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : The maternal outcome in placenta accreta: the significance of antenatal diagnosis and non-separation of placenta at delivery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33784573" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Placenta accreta spectrum disorder: updates on anesthetic and surgical management strategies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23339591" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Comparison between emergent and elective delivery in women with placenta accreta.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21419387" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Predictors of massive blood loss in women with placenta accreta.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36701609" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Red Blood Cell Transfusion in Patients With Placenta Accreta Spectrum: A Systematic Review and Meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34391750" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Urologic morbidity associated with placenta accreta spectrum surgeries: single-center experience with a multidisciplinary team.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37401769" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Urological complications in women undergoing Cesarean section for placenta accreta spectrum disorders: systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36201777" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Prophylactic Ureteral Stent Placement and Urinary Injury During Hysterectomy for Placenta Accreta Spectrum.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37549736" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Prophylactic ureteral stent placement for the prevention of genitourinary tract injury during hysterectomy for placenta accreta spectrum: systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21168325" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Multiple complications following the use of prophylactic internal iliac artery balloon catheterisation in a patient with placenta percreta.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21840207" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Anesthetic considerations for placenta accreta.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28258943" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Anaesthesia for abnormally invasive placenta: a single-institution case series.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30255598" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Role of interventional radiology in pregnancy complicated by placenta accreta spectrum disorder: systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Outcomes of balloon occlusion in the University of California Morbidly Adherent Placenta Registry
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34736088" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Clinical and hemodynamic insights into the use of internal iliac artery balloon occlusion as a prophylactic technique for treating postpartum hemorrhage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16232175" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Arterial embolization and prophylactic catheterization for the treatment for severe obstetric hemorrhage*.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17904978" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Case-control comparison of cesarean hysterectomy with and without prophylactic placement of intravascular balloon catheters for placenta accreta.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17018488" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Arterial embolus during common iliac balloon catheterization at cesarean hysterectomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17383300" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : A propensity analysis of the risk of vascular complications after cardiac catheterization procedures with the use of vascular closure devices.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21793748" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Case records of the Massachusetts General Hospital. Case 23-2011. A 40-year-old pregnant woman with placenta accreta who declined blood products.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19922901" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Surgical management of placenta accreta: a cohort series and suggested approach.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29401189" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Prophylactic use of resuscitative endovascular balloon occlusion of the aorta in women with abnormal placentation: A systematic review, meta-analysis, and case series.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29026545" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Resuscitative endovascular balloon occlusion of the aorta as an adjunct for hemorrhagic shock due to uterine rupture: a case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28355242" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Fluoroscopy-free Resuscitative Endovascular Balloon Occlusion of the Aorta (REBOA) for controlling life threatening postpartum hemorrhage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29439891" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Resuscitative Endovascular Balloon Occlusion of the Aorta Using a Low-Profile Device is Easy and Safe for Emergency Physicians in Cases of Life-Threatening Hemorrhage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26816219" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : A systematic review of the use of resuscitative endovascular balloon occlusion of the aorta in the management of hemorrhagic shock.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30258488" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Resuscitative endovascular balloon occlusion of the aorta deployed by acute care surgeons in patients with morbidly adherent placenta: a feasible solution for two lives in peril.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33926349" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : REBOA placement for placenta accreta spectrum: patient selection and utilization.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33207992" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Arterial thrombosis after REBOA use in placenta accreta spectrum: a case series.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29079144" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Society for Maternal-Fetal Medicine (SMFM) Consult Series #44: Management of bleeding in the late preterm period.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20859146" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Effectiveness of timing strategies for delivery of individuals with placenta previa and accreta.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3875064" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Hypogastric artery ligation for obstetric hemorrhage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16242133" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Hypogastric artery ligation for intractable pelvic hemorrhage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21557692" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : The effectiveness of bilateral hypogastric artery ligation for obstetric hemorrhage in three different underlying conditions and its impact on future fertility.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20177283" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Maternal outcome after conservative treatment of placenta accreta.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15255846" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Anterior placenta percreta: surgical approach, hemostasis and uterine repair.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22326782" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : The Triple-P procedure as a conservative surgical alternative to peripartum hysterectomy for placenta percreta.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24266548" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Management of placenta percreta: a review of published cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25402727" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Prevention of postpartum hemorrhage and hysterectomy in patients with morbidly adherent placenta: a cohort study comparing outcomes before and after introduction of the Triple-P procedure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25935779" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Conservative management of morbidly adherent placenta: expert review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34914894" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Conservative management or cesarean hysterectomy for placenta accreta spectrum: the PACCRETA prospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24768979" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Conservative management of placenta accreta: hysteroscopic resection of retained tissues.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24138386" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Delayed hysteroscopic resection of retained tissues and uterine conservation after conservative treatment for placenta accreta.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22024264" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Hysteroscopic management of residual trophoblastic tissue is superior to ultrasound-guided curettage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27355003" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Robotically assisted delayed total laparoscopic hysterectomy for placenta percreta.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28852530" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Multidisciplinary approach to manage antenatally suspected placenta percreta: updated algorithm and patient outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31469990" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Outcomes following a clinical algorithm allowing for delayed hysterectomy in the management of severe placenta accreta spectrum.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21638046" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Invasive placentation and uterus preserving treatment modalities: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35065016" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Conservative management of placenta accreta spectrum: is it time?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20152971" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Fertility and obstetric outcome after conservative management of placenta accreta.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20833739" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Fertility and pregnancy outcomes following conservative treatment for placenta accreta.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22014777" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Planned caesarean hysterectomy versus "conserving" caesarean section in patients with placenta accreta.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23313722" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Placenta accreta: risk factors, perinatal outcomes, and consequences for subsequent births.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36934974" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Focal-occult placenta accreta: a clandestine source of maternal morbidity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32771462" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Conservative surgical approach: The Triple P procedure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31034579" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Severe hypocalcemia during surgery for placenta accreta spectrum: The case for empiric replacement.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
